Core Insights - The company reported strong sales growth for the first nine months of 2025, prompting an upward revision of its full-year financial guidance [1][2] - The CEO highlighted robust performance across three therapeutic areas, with increasing contributions from the rare liver disease segment [1] - The company is optimistic about the Phase II LANTIC trial data for its innovative long-acting molecule IPN10200 in the aesthetic medicine sector [1] Financial Performance - For the first nine months of 2025, the company achieved a year-on-year sales growth of approximately 10.0%, up from a previous expectation of over 7.0% [2] - The company has adjusted its full-year financial guidance based on strong performance metrics [2] Acquisition Details - The company signed a final equity acquisition agreement to acquire ImCheck Therapeutics, a French biotech firm focused on next-generation cancer immunotherapy [2] - The acquisition centers on the ICT01 project, which targets acute myeloid leukemia (AML) and is expected to enter Phase IIb/III trials in 2026 [2] - The deal includes an upfront cash payment of €350 million, with additional payments contingent on regulatory approvals and sales milestones [2]

Core Insights - Ipsen is acquiring ImCheck Therapeutics for €350 million ($406.6 million) with potential total transaction value reaching €1 billion ($1.16 billion) based on regulatory milestones and sales targets [1][2][3] Group 1: Transaction Details - The acquisition will be executed by Ipsen SAS' fully owned subsidiary and is expected to close by the end of Q1 2026, pending regulatory approvals [2] - Legal counsel for Ipsen is provided by Allen & Overy Shearman, while ImCheck has engaged Centerview Partners as its exclusive financial advisor [2][3] Group 2: Focus of Acquisition - The primary focus of the acquisition is ImCheck's ICT01, a Phase I/II program targeting acute myeloid leukaemia patients not suitable for intensive chemotherapy [3] - ICT01 received orphan drug status from both the European Medicines Agency and the US Food and Drug Administration in July 2025 [3] Group 3: Strategic Implications - Ipsen's CEO highlighted the acquisition as an opportunity to expand its oncology pipeline and emphasized confidence in advancing ICT01 into a Phase IIb/III trial in 2026 [4]

Core Points - Ipsen has announced a definitive agreement to acquire ImCheck Therapeutics, a French biotechnology company specializing in next-generation immuno-oncology therapies, focusing on the ICT01 program for treating acute myeloid leukemia (AML) [1][5][6] - The acquisition aims to enhance Ipsen's oncology R&D portfolio and is expected to facilitate the launch of a Phase IIb/III trial for ICT01 in 2026, leveraging promising data from ongoing clinical trials [3][6] Transaction Details - The acquisition involves a payment of €350 million at closing, with potential total payments reaching up to €1 billion contingent on regulatory approvals and sales milestones [5][6] - The transaction is expected to be finalized by the end of Q1 2026, subject to customary closing conditions [7] Clinical Program Insights - ICT01 is a first-in-class monoclonal antibody targeting BTN3A, showing high therapeutic response rates in ongoing Phase I/II trials, particularly for patients ineligible for intensive chemotherapy [2][3][6] - The EVICTION trial data indicated that the combination of ICT01 with venetoclax and azacitidine resulted in nearly double the response rate compared to historical data for standard care [3][6] Company Background - Ipsen is a global biopharmaceutical group focused on developing innovative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of experience in drug development [11] - ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, with the potential to transform treatments in oncology and other fields [12][14]

Core Viewpoint - Ipsen has entered into a definitive share purchase agreement to acquire ImCheck Therapeutics, focusing on the development of next-generation immuno-oncology therapies, particularly the lead program ICT01 for acute myeloid leukemia (AML) patients who cannot tolerate intensive chemotherapy [1][3]. Company Overview - Ipsen is a global biopharmaceutical company dedicated to transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [11]. - ImCheck Therapeutics is a private French biotechnology company developing immunotherapeutic antibodies targeting butyrophilins, with a focus on enhancing the immune response against cancer [13][14]. Acquisition Details - The acquisition involves a payment of 350 million euros at closing, with potential total consideration up to 1 billion euros based on regulatory approvals and sales milestones [5][8]. - The transaction is expected to close by the end of Q1 2026, pending regulatory approvals [6]. Clinical Program Focus - The lead program ICT01 is a first-in-class monoclonal antibody targeting BTN3A, which has shown promising interim data in the Phase I/II EVICTION trial for AML, achieving high treatment responses [3][8]. - ICT01 is designed to activate γ9δ2 T cells, enhancing the immune response against tumors, and has received Orphan Drug Designations from both the U.S. FDA and European Medicines Agency [1][10]. Market Need - There is a significant unmet medical need for new therapies in AML, particularly for patients who are unfit for intensive chemotherapy, highlighting the urgency for innovative treatments [2].